Physician profile
Mithil Gowda Suresh
NPI 1164093282
$1,542.53
in general payments reported to CMS, 2019-2025
22 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.77 · 2022: $456 · 2023: $183 · 2024: $384 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $236.85 | 2021-2025 | Opdivo, Camzyos |
| Abbvie INC. | $218.00 | 2023-2025 | Avycaz, Dalvance, Teflaro |
| Lilly USA, LLC | $125.00 | 2025 | Omvoh |
| Gilead Sciences, INC. | $124.29 | 2021-2022 | |
| Pfizer INC. | $114.00 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.20 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.77 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Grifols USA, LLC | $81.68 | 2024 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $71.88 | 2022-2024 | Entyvio |
| Glaxosmithkline, LLC. | $65.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.84 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $47.65 | 2023-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $33.75 | 2024 | |
| Merck Sharp & Dohme LLC | $24.98 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.90 | 2025 | Onpattro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $24.02 | 2025 | |
| Dexcom, INC. | $23.06 | 2025 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $22.88 | 2025 | Veltassa |
| Actelion Pharmaceuticals US, INC. | $19.05 | 2025 | Opsumit |
| Amgen INC. | $18.93 | 2025 | |
| Karyopharm Therapeutics INC. | $18.91 | 2024 | Xpovio |
| Incyte Corporation | $17.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mithil Gowda Suresh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.